Mercer Global Advisors
TVRD

Mercer Global Advisors’s Tvardi Therapeutics TVRD Stock Holding History

Mercer Global Advisors’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.43K Buy
+753
New +$2.36K ﹤0.01% 5669

Other funds holding TVRD

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AFG
American Financial Group Cincinnati, Ohio $284M AUM 12.01% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DWAM
Duncan Williams Asset Management Memphis, Tennessee $444M AUM 24.78% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Mercer Global Advisors's TVRD Position: Q2 2026 in Review

Mercer Global Advisors opened a new position in Tvardi Therapeutics (TVRD) in Q2 2026: 753 shares worth $1.43K. The stake represents ﹤0.01% of the portfolio and ranks #5669 among its holdings.

43 funds tracked by Wall St. Rank hold TVRD as of Q2 2026.

  • Mercer Global Advisors held 753 shares of Tvardi Therapeutics worth $1.43K as of Q2 2026.
  • Tvardi Therapeutics was a new Mercer Global Advisors position in Q2 2026.
  • Tvardi Therapeutics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #5669 holding.
  • 43 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.